Abstract

The invention relates to the field of dairy technology. The invention specifically relates to a Streptococcus thermophilus starter strain and composition comprising such strain, to methods to produce a fermented milk product using such strain or composition and to dairy products produced using such strain or composition.

IPC Classes  ?

• A23C 9/123 - Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
• C12N 1/20 - Bacteria; Culture media therefor

Abstract

The present invention relates to a new intermediate, which can be used in the process for producing β-carotene.

IPC Classes  ?

• C07F 9/54 - Quaternary phosphonium compounds
• C07C 403/24 - Derivatives of cyclohexane or of a cyclohexene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene rings, e.g. vitamin A, beta-carotene, beta-i having side-chains substituted by six-membered non-aromatic rings, e.g. beta-carotene

Abstract

The present invention relates to a method for reducing asperphenamate concentration in a nutritional composition comprising asperphenamate, the method comprising the step of providing a microorganism comprising a polynucleotide having at least 95% identity to the nucleotide sequence of SEQ ID NO: 1 and/or SEQ ID NO: 2 to a nutritional composition comprising asperphenamate.

IPC Classes  ?

• A23K 10/18 - Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
• A23L 5/20 - Removal of unwanted matter, e.g. deodorisation or detoxification
• C12N 1/16 - Yeasts; Culture media therefor

Abstract

The present invention relates to a process for producing β-carotene in specific solvents.

IPC Classes  ?

• C07C 403/24 - Derivatives of cyclohexane or of a cyclohexene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene rings, e.g. vitamin A, beta-carotene, beta-i having side-chains substituted by six-membered non-aromatic rings, e.g. beta-carotene

Abstract

The present invention relates to process for producing β-carotene in a specific solvent.

IPC Classes  ?

• C07C 403/24 - Derivatives of cyclohexane or of a cyclohexene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene rings, e.g. vitamin A, beta-carotene, beta-i having side-chains substituted by six-membered non-aromatic rings, e.g. beta-carotene

Abstract

The present invention relates to a formulation, which comprises a fat-soluble vitamin and which can be used for fortifying early life nutrition products.

IPC Classes  ?

• A23L 29/30 - Foods or foodstuffs containing additives; Preparation or treatment thereof containing starch hydrolysates, e.g. dextrin
• A23L 33/115 - Fatty acids or derivatives thereof; Fats or oils
• A23L 33/00 - Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
• A61K 31/07 - Retinol compounds, e.g. vitamin A
• A61K 31/122 - Ketones having the oxygen atom directly attached to a ring, e.g. quinones, vitamin K1, anthralin
• A61K 31/355 - Tocopherols, e.g. vitamin E
• A61K 31/59 - Compounds containing 9,10-seco-cyclopenta[a]hydro- phenanthrene ring systems

Abstract

The present application concerns methods and uses for improving the balance of beneficial and deleterious bacteria in the gastrointestinal tract of aquatic species. It also concerns a method of culturing an aquaculture of an aquatic species, comprising improving the balance of beneficial and deleterious bacteria in the gastrointestinal tract of said aquatic species by the means of a composition comprising a protease.

IPC Classes  ?

• A61K 38/48 - Hydrolases (3) acting on peptide bonds (3.4)
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
• A61K 38/16 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
• A61P 31/04 - Antibacterial agents
• A23K 20/189 - Enzymes
• A23K 50/80 - Feeding-stuffs specially adapted for particular animals for aquatic animals, e.g. fish, crustaceans or molluscs

Abstract

The present invention relates to novel host cells capable of degrading starch and/or utilizing starch as a carbon source wherein said host cell comprising one or more of the following sequences: (a) a polypeptide having at least 97% identity to the polypeptide set forth in SEQ ID NO: 1 or SEQ ID NO: 2; (b) a polypeptide having at least 96% identity to the polypeptide set forth in SEQ ID NO: 3 or SEQ ID NO: 4, wherein said polypeptide is capable of binding starch and/or having alpha-amylase enzymatic activity; (c) one or more polynucleotides encoding said one or more polypeptides as in (a)-(b). Particularly, the present invention relates to novel probiotic strains of Bifidobacterium adolescentis selected from the group consisting of: Bifidobacterium adolescentis designated strain "KI BAD2" having Accession No.: DSM 34061 and Bifidobacterium adolescentis designated strain "KI BAD4" having Accession No.: DSM 34065 as well as methods and used thereof for starch degradation and modifying gut flora in non-human mammals.

IPC Classes  ?

• C07K 14/195 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
• C12N 1/20 - Bacteria; Culture media therefor
• A61K 35/745 - Bifidobacteria
• A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics
• C12N 9/28 - Alpha-amylase from microbial source, e.g. bacterial amylase
• C12N 9/26 - Hydrolases (3.) acting on glycosyl compounds (3.2) acting on alpha-1, 4-glucosidic bonds, e.g. hyaluronidase, invertase, amylase

Abstract

The present invention relates to hair dye compositions comprising a specific mixture of branched and linear saturated C15-C19 alkanes, an ester of a fatty acid and dextrin. It has been shown that these hair dye compositions lead to a significant increase of colour resistance of dyed hair.

IPC Classes  ?

• A61K 8/31 - Hydrocarbons
• A61K 8/73 - Polysaccharides
• A61Q 5/10 - Preparations for permanently dyeing the hair
• A61Q 5/00 - Preparations for care of the hair
• A61Q 5/06 - Preparations for styling the hair, e.g. by temporary shaping or colouring

Abstract

The present disclosure relates to a method for producing oligosaccharides where the method combines a fermentation process and an enzymatic reaction in the medium of the fermentation, thereby enabling the formation of the oligosaccharide in the fermentation medium of an ongoing fermentation. The method is in particular suitable for the generation of complex oligosaccharides.

IPC Classes  ?

• A23L 33/00 - Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
• C07H 3/06 - Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
• C12N 15/52 - Genes encoding for enzymes or proenzymes
• C12P 19/18 - Preparation of compounds containing saccharide radicals produced by the action of a glycosyl transferase, e.g. alpha-, beta- or gamma-cyclodextrins
• C12P 19/04 - Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
• C12N 9/10 - Transferases (2.)
• C12N 9/24 - Hydrolases (3.) acting on glycosyl compounds (3.2)

Abstract

The present invention relates to a formulation, which comprises a fat-soluble vitamin and which can be used for fortifying food products (especially staple food).

IPC Classes  ?

• A23L 33/10 - Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
• A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives
• A23L 33/155 - Vitamins A or D

Abstract

The present invention relates to a formulation, which comprises a fat-soluble vitamin and which can be used for fortifying food products (especially staple food).

IPC Classes  ?

• A23L 33/10 - Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
• A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives
• A23L 33/155 - Vitamins A or D

Abstract

The present invention relates to hair care compositions comprising a specific mixture of branched and linear saturated C15-C19 alkanes, an ester of a fatty acid and dextrin and a cationic emulsifier. It has been shown that these hair care compositions lead to a significant increase of colour resistance of dyed hair.

IPC Classes  ?

• A61Q 5/00 - Preparations for care of the hair
• A61K 8/31 - Hydrocarbons
• A61K 8/41 - Amines
• A61K 8/73 - Polysaccharides
• A61Q 5/12 - Preparations containing hair conditioners

Abstract

The present invention relates to new specific 2'-fucosyllactose propionate compounds, to a new and improved synthesis of specific 2'-fucosyllactose propionates as well their use. Propionate compounds are very useful compounds.

IPC Classes  ?

• C07H 1/00 - Processes for the preparation of sugar derivatives
• C07H 13/04 - Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms

Abstract

The present invention relates to a laser-weldable polyester composition, more particular to a laser-weldable fibre-reinforced polybutylene terephthalate composition comprising: (A) a polybutylene terephthalate resin (PBT); (B) glass fibres; and (C) an alkali metal salt of a fatty acid with 24 – 40 carbon atoms; wherein component (B) is present in an amount in a range of 15 – 100 parts by weight, relative to 100 parts by weight of component (A) and component (C) is present in an amount in a range of 1.75 – 4.5 parts by weight, relative to 100 parts by weight of component (A). The invention also relates to - a process for preparing the laser-weldable fibre-reinforced polyester composition, - a process for making a moulded part from the laser-weldable fibre-reinforced polyester composition, - a laser transparent moulded part made of the laser-weldable fibre-reinforced polyester composition, to - a process for laser welding the laser transparent moulded part made of the laser-weldable fibre-reinforced polyester composition on laser-light-absorbent polymeric substrate, and - a composite article comprising the moulded article made of the laser-weldable fibre-reinforced polyester composition bonded by laser welding on a laser-light- absorbent polymeric substrate.

IPC Classes  ?

• B29C 65/16 - Laser beam
• C08K 5/098 - Metal salts of carboxylic acids
• C08L 67/02 - Polyesters derived from dicarboxylic acids and dihydroxy compounds
• B29C 65/00 - Joining of preformed parts; Apparatus therefor
• B29K 67/00 - Use of polyesters as moulding material
• B29K 105/12 - Condition, form or state of moulded material containing reinforcements, fillers or inserts of short lengths, e.g. chopped filaments, staple fibres or bristles
• B29K 105/16 - Fillers
• B29K 309/08 - Glass

Abstract

The present invention relates to sunscreen compositions containing bis-ethylhexyloxyphenol methoxyphenyl triazine (BEMT), diethylhexyl sebacate and one or more alkanediol with the proviso that the composition is free of ethylhexyl methoxycinnamate. Said compositions exhibit a reduced soaping effect and thus a more appealing skin feel and look.

IPC Classes  ?

• A61K 8/06 - Emulsions
• A61K 8/37 - Esters of carboxylic acids
• A61K 8/49 - Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
• A61Q 17/04 - Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
• A61K 8/34 - Alcohols

Abstract

The present invention relates to a solid formulation comprising β-carotene with a high amount of a specific stereochemical form. Furthermore, the present invention relates to a process of production of such a specific formulation.

IPC Classes  ?

• A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives
• A23L 33/15 - Vitamins
• A61K 31/355 - Tocopherols, e.g. vitamin E
• A61K 31/015 - Hydrocarbons carbocyclic
• C12P 23/00 - Preparation of compounds containing a cyclohexene ring having an unsaturated side chain containing at least ten carbon atoms bound by conjugated double bonds, e.g. carotenes

Abstract

The present invention relates to a method reducing necrotic enteritis effect in a bird comprising administering an oligosaccharide preparation, and to an oligosaccharide preparation for use in treatment, amelioration and/or prophylaxis of a bird suffering from necrotic enteritis or in risk thereof.

IPC Classes  ?

• A61K 31/702 - Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system

Abstract

The present invention relates to a specific multicomponent crystalline system (co- crystal) comprising Urolithin A as one of the components produced by a specific process.

IPC Classes  ?

• C07D 311/80 - Dibenzopyrans; Hydrogenated dibenzopyrans
• A61K 31/37 - Coumarins, e.g. psoralen

Abstract

The present invention relates to a specific multicomponent crystalline system (co- crystal) comprising Urolithin A as one of the components produced by a specific process.

IPC Classes  ?

• C07D 311/80 - Dibenzopyrans; Hydrogenated dibenzopyrans
• A61K 31/37 - Coumarins, e.g. psoralen

Abstract

The present invention relates to the production of fucosylated Human Milk Oligosaccharides (HMOs), and in particular to the production of complex fucosylated HMOs with five or more monosaccharide units, such as LNFP-V and LNDFH-II, from precursor oligosaccharides and the genetic engineering cells and α-1,3(4)-fucosyltransferases suitable for use in said production of suitable for use in said production, as well as to methods for producing said fucosylated HMOs.

IPC Classes  ?

• C12N 9/10 - Transferases (2.)

Abstract

Bifidobacterium spnadC, nadDnadEnadE) and at least one fucosylated oligosaccharide to said subject.

IPC Classes  ?

• A61K 35/745 - Bifidobacteria
• A61K 31/702 - Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
• A61P 3/00 - Drugs for disorders of the metabolism
• A61P 19/00 - Drugs for skeletal disorders
• A61P 25/00 - Drugs for disorders of the nervous system

Abstract

The present invention relates to the production of fucosylated Human Milk Oligosaccharides (HMOs), and in particular to the production of complex fucosylated HMOs with five or more monosaccharide units such as LNFP-II, LNFP-III and LNDFH-I from precursor oligosaccharides and the genetic engineering of suitable cells for use in said production, as well as to methods for producing said fucosylated HMOs.

IPC Classes  ?

• C12N 9/10 - Transferases (2.)

Abstract

A lack of vitamin D is a possible reason for poor response to vortioxetine treatment. Many vortioxetine low-responders and vortioxetine non-responders benefit from vitamin D supplementation. The pharmaceutical combination of the invention is a pharmaceutical combination for simultaneous or sequential administration comprising vitamin D and vortioxetine. Thereby, vitamin D is preferably cholecalciferol or calcifediol. The preferred vortioxetine is vortioxetine hydrobromide.

IPC Classes  ?

• A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
• A61K 31/575 - Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
• A61K 31/592 - 9,10-Secoergostane derivatives, e.g. ergocalciferol, vitamin D2
• A61K 31/593 - 9,10-Secocholestane derivatives, e.g. cholecalciferol, vitamin D3
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 25/24 - Antidepressants

Abstract

The present disclosure relates to the production of fucosylated Human Milk Oligosaccharides (HMOs). In particular, it relates to alpha-1,3-fucosyltransferases for the production of lacto-N- fucopentaose III (LNFP-III), as well as to genetically engineered cells and their use in said production. Preferably the alpha-1,3- fucosyltransferases described herein do not fucosylate the reducing end of the acceptor oligosaccharide used as substrate for the alpha-1,3- fucosyltransferases.

IPC Classes  ?

• C12N 9/10 - Transferases (2.)

Abstract

The invention relates to a non-fermented plant-based beverage, characterized in that it comprises one or more human milk oligosaccharides.

IPC Classes  ?

• A23C 11/10 - Milk substitutes, e.g. coffee whitener compositions containing at least one non-milk component as source of fats or proteins containing or not lactose but no other milk components as source of fats, carbohydrates or proteins
• A23L 2/38 - Other non-alcoholic beverages
• A23L 2/52 - Adding ingredients
• A23L 11/60 - Drinks from legumes, e.g. lupine drinks
• A23L 11/65 - Soy drinks
• A23L 33/15 - Vitamins
• A23L 33/185 - Vegetable proteins
• A23L 33/21 - Addition of substantially indigestible substances, e.g. dietary fibres

Abstract

The present invention relates to methods of making baked goods using protein arginine deiminase, baked goods compositions treated with protein arginine deiminase, and pre-mix compositions containing protein arginine deiminase. The protein arginine deiminase can also be combined with enzymes such as lipases, phospholipases, etc. The baked goods involved provide benefits such as increased volume.

IPC Classes  ?

• A21D 2/08 - Treatment of flour or dough by adding materials thereto before or during baking by adding organic substances
• A21D 2/26 - Proteins
• A21D 8/04 - Methods for preparing dough; Treating dough prior to baking treating dough with microorganisms or enzymes

Abstract

The present invention relates to the production of sialylated Human Milk Oligosaccharides (HMOs), in particular to the production of sialyl-lacto-N-neotetraose (LST-c), from precursor oligosaccharides and the genetic engineering of suitable cells for use in said production, as well as to methods for producing said sialylated HMOs.

IPC Classes  ?

• C12P 19/26 - Preparation of nitrogen-containing carbohydrates

Abstract

The present invention relates to the use of human milk oligosaccharides (HMOs) for improving the regeneration and/or viability of Lactobacillus bacteria in acidic environments. HMOs were found to increase the number of viable Lactobacillus bacteria upon their rehydration (regeneration) in acidic liquids. This improves probiotic potential of these bacteria in food, beverages, dietary supplements, and oral pharmaceuticals, as their viability during preparation for consumption, after ingestion, and/or along the path through the gastrointestinal tract increases.

IPC Classes  ?

• A23L 29/00 - Foods or foodstuffs containing additives; Preparation or treatment thereof
• A23L 29/30 - Foods or foodstuffs containing additives; Preparation or treatment thereof containing starch hydrolysates, e.g. dextrin
• A23L 33/125 - Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing starch hydrolysates
• A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics
• C12N 1/04 - Preserving or maintaining viable microorganisms
• C12N 1/20 - Bacteria; Culture media therefor
• C12P 19/00 - Preparation of compounds containing saccharide radicals
• C12P 19/18 - Preparation of compounds containing saccharide radicals produced by the action of a glycosyl transferase, e.g. alpha-, beta- or gamma-cyclodextrins
• C12R 1/225 - Lactobacillus

Abstract

The present invention relates to the use of human milk oligosaccharides (HMOs) for improving the regeneration and/or viability of Lactobacillus rhamnosus bacteria in acidic environments. HMOs were found to increase the number of viable Lactobacillus rhamnosus bacteria upon their rehydration (regeneration) in acidic liquids. This improves probiotic potential of these bacteria in food, beverages, dietary supplements, and oral pharmaceuticals, as their viability during preparation for consumption, after ingestion, and/or along the path through the gastrointestinal tract increases.

IPC Classes  ?

• A23L 29/00 - Foods or foodstuffs containing additives; Preparation or treatment thereof
• A23L 29/30 - Foods or foodstuffs containing additives; Preparation or treatment thereof containing starch hydrolysates, e.g. dextrin
• A23L 33/125 - Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing starch hydrolysates
• A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics

Abstract

The present invention relates to a mixture of human milk oligosaccharides ("HMOs") comprising five fucosylated HMOs, as well as to an enzymatic process for making said mixture, wherein said synthesis comprises an α1-3/4-transfucosidase enzymatic reaction between HMO donors and acceptors.

IPC Classes  ?

• A23L 29/00 - Foods or foodstuffs containing additives; Preparation or treatment thereof
• A23L 29/30 - Foods or foodstuffs containing additives; Preparation or treatment thereof containing starch hydrolysates, e.g. dextrin
• A23L 33/125 - Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing starch hydrolysates
• A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics
• C12N 1/04 - Preserving or maintaining viable microorganisms
• C12N 1/20 - Bacteria; Culture media therefor
• C12P 19/00 - Preparation of compounds containing saccharide radicals
• C12P 19/18 - Preparation of compounds containing saccharide radicals produced by the action of a glycosyl transferase, e.g. alpha-, beta- or gamma-cyclodextrins
• C12R 1/225 - Lactobacillus

Abstract

The present invention relates to the use of human milk oligosaccharides (HMOs) for improving the regeneration and/or viability of Bifidobacteria in acidic environments. HMOs were found to increase the number of viable Bifidobacteria upon their rehydration (regeneration) in acidic liquids. This improves probiotic potential of these bacteria in food, beverages, dietary supplements, and oral pharmaceuticals, as their viability during preparation for consumption, after ingestion, and/or along the path through the gastrointestinal tract increases.

IPC Classes  ?

• A23L 29/00 - Foods or foodstuffs containing additives; Preparation or treatment thereof
• A23L 29/30 - Foods or foodstuffs containing additives; Preparation or treatment thereof containing starch hydrolysates, e.g. dextrin
• A23L 33/125 - Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing starch hydrolysates
• A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics
• C12N 1/04 - Preserving or maintaining viable microorganisms
• C12N 1/20 - Bacteria; Culture media therefor
• C12P 19/00 - Preparation of compounds containing saccharide radicals
• C12P 19/18 - Preparation of compounds containing saccharide radicals produced by the action of a glycosyl transferase, e.g. alpha-, beta- or gamma-cyclodextrins
• C12R 1/225 - Lactobacillus

Abstract

LactobacillusL. crispatusS. epidermidisS. epidermidis against UV radiation.

IPC Classes  ?

• A61K 8/27 - Zinc; Compounds thereof
• A61K 8/35 - Ketones, e.g. quinones, benzophenone
• A61K 8/40 - Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
• A61K 8/49 - Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
• A61K 31/12 - Ketones
• A61K 31/277 - Nitriles; Isonitriles having a ring, e.g. verapamil
• A61K 31/315 - Zinc compounds
• A61K 31/395 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
• A61P 17/16 - Emollients or protectives, e.g. against radiation
• A61Q 17/04 - Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
• A61Q 19/00 - Preparations for care of the skin

Abstract

LactobacillusLactobacillus crispatusL. crispatusS. EpidermidisS. Epidermidis against UV radiation to foster the maintenance of a healthy skin microbiome upon UV irradiation.

IPC Classes  ?

• A61K 8/27 - Zinc; Compounds thereof
• A61K 8/35 - Ketones, e.g. quinones, benzophenone
• A61K 8/40 - Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
• A61K 8/49 - Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
• A61K 31/12 - Ketones
• A61K 31/277 - Nitriles; Isonitriles having a ring, e.g. verapamil
• A61K 31/315 - Zinc compounds
• A61K 31/395 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
• A61P 17/16 - Emollients or protectives, e.g. against radiation
• A61Q 17/04 - Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
• A61Q 19/00 - Preparations for care of the skin

Abstract

The present invention relates to the use of selected UV filters selected from the group consisting of octocrylene, ethylhexyl salicylate and butyl methoxydibenzoylmethane to reduce the abundance of C. acnes strains in a skin microbiome after UV radiation. Said use is suitable to prevent and or treat the progression of acne, in particular the progression of acne exacerbated by sunscreen application.

IPC Classes  ?

• A61K 8/37 - Esters of carboxylic acids
• A61K 31/12 - Ketones
• A61K 31/235 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
• A61K 31/275 - Nitriles; Isonitriles
• A61K 8/40 - Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
• A61K 8/35 - Ketones, e.g. quinones, benzophenone
• A61Q 19/00 - Preparations for care of the skin
• A61P 17/10 - Anti-acne agents
• A61K 8/34 - Alcohols
• A61Q 17/04 - Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations

Abstract

The present invention relates to the biosynthetic production of heterologous products in a genetically engineered cell comprising heterologous nucleic acids encoding a heterologous product and/or a polypeptide required for the production of the heterologous products, wherein the expression of the growth phase and/or stationary phase RNA polymerase sigma factors in said cell is modulated.

IPC Classes  ?

• C12N 15/70 - Vectors or expression systems specially adapted for E. coli
• C12P 19/18 - Preparation of compounds containing saccharide radicals produced by the action of a glycosyl transferase, e.g. alpha-, beta- or gamma-cyclodextrins
• C12N 9/10 - Transferases (2.)

Abstract

The present invention relates to a process for the preparation of alkoxylated 2, 5-di hydrofuran. The process is carried out in an electrochemical cell reactor with a vertical flow.

IPC Classes  ?

• C25B 3/07 - Oxygen containing compounds
• C25B 3/23 - Oxidation
• C25B 3/29 - Coupling reactions
• C25B 9/13 - Single electrolytic cells with circulation of an electrolyte
• C25B 11/042 - Electrodes formed of a single material
• C25B 11/043 - Carbon, e.g. diamond or graphene
• C07D 307/32 - Oxygen atoms

Abstract

The invention relates to a method for the purification of a neutral or sialylated human milk oligosaccharide (HMO) from a fermentation broth. Moreover, the invention also concerns neutral or sialylated HMOs obtained by the inventive method, as well as its use in food, feed, and medical application.

IPC Classes  ?

• B01D 61/04 - Feed pretreatment
• B01D 15/26 - Selective adsorption, e.g. chromatography characterised by the separation mechanism
• B01D 61/58 - Multistep processes
• B01J 20/26 - Synthetic macromolecular compounds
• B01J 20/285 - Porous sorbents based on polymers
• B01J 41/07 - Processes using organic exchangers in the weakly basic form
• C07H 1/08 - Separation; Purification from natural products
• C12M 1/00 - Apparatus for enzymology or microbiology
• C12P 7/18 - Preparation of oxygen-containing organic compounds containing a hydroxy group acyclic polyhydric
• B01D 61/02 - Reverse osmosis; Hyperfiltration
• B01D 61/14 - Ultrafiltration; Microfiltration

Abstract

The invention relates to a method for the purification of a neutral or sialylated human milk oligosaccharide (HMO) from a fermentation broth. Moreover, the invention also concerns neutral or sialylated HMOs obtained by the inventive method, as well as its use in food, feed, and medical application.

IPC Classes  ?

• B01D 61/04 - Feed pretreatment
• B01D 15/26 - Selective adsorption, e.g. chromatography characterised by the separation mechanism
• B01D 61/58 - Multistep processes
• B01J 20/26 - Synthetic macromolecular compounds
• B01J 20/285 - Porous sorbents based on polymers
• B01J 41/07 - Processes using organic exchangers in the weakly basic form
• C07H 1/08 - Separation; Purification from natural products
• C12M 1/00 - Apparatus for enzymology or microbiology
• C12P 7/18 - Preparation of oxygen-containing organic compounds containing a hydroxy group acyclic polyhydric
• B01D 61/02 - Reverse osmosis; Hyperfiltration
• B01D 61/14 - Ultrafiltration; Microfiltration

Abstract

Bacillus coagulansBacillus coagulans in the intestinal tract.

IPC Classes  ?

• A61K 31/51 - Thiamines, e.g. vitamin B1
• A61K 35/742 - Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
• A61P 1/12 - Antidiarrhoeals
• A61P 11/00 - Drugs for disorders of the respiratory system

Abstract

The present invention relates to a combination comprising vitamin C and Bifidobacterium animalis ssp. lactis and its use for improving gut health in animals and humans. It was found that a combination of vitamin C and Bifidobacterium animalis ssp. lactis, when delivered to the large intestine, increases the abundance of Bifidobacterium bifidum bacteria in the intestinal tract.

IPC Classes  ?

• A61K 31/375 - Ascorbic acid, i.e. vitamin C; Salts thereof
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61P 17/00 - Drugs for dermatological disorders
• A61K 35/745 - Bifidobacteria

Abstract

Lactobacillus rhamnosusLactobacillus rhamnosusActinobacteria, BifidobacteriaceaeBifidobacteriumBifidobacterium bacteria in the intestinal tract.

IPC Classes  ?

• A61K 31/375 - Ascorbic acid, i.e. vitamin C; Salts thereof
• A61K 35/747 - Lactobacilli, e.g. L. acidophilus or L. brevis
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• A61P 17/00 - Drugs for dermatological disorders
• A61P 3/02 - Nutrients, e.g. vitamins, minerals
• A61P 35/00 - Antineoplastic agents
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• A61P 3/06 - Antihyperlipidemics

Abstract

The present invention relates to a combination comprising vitamin C and Lactobacillus rhamnosus and its use for improving gut health in animals and humans. It was found that a combination of vitamin C and Lactobacillus rhamnosus, when delivered to the large intestine, increases the abundance of beneficial Firmicutes, Lachnospiraceae, Blautia bacteria in the intestinal tract.

IPC Classes  ?

• A61K 31/375 - Ascorbic acid, i.e. vitamin C; Salts thereof
• A61K 35/747 - Lactobacilli, e.g. L. acidophilus or L. brevis
• A61P 1/18 - Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
• A61P 3/04 - Anorexiants; Antiobesity agents
• A61P 5/50 - Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
• A61P 17/00 - Drugs for dermatological disorders
• A61P 19/00 - Drugs for skeletal disorders
• A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
• A61P 31/18 - Antivirals for RNA viruses for HIV
• A61P 35/00 - Antineoplastic agents
• A61P 37/00 - Drugs for immunological or allergic disorders
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• A61P 3/02 - Nutrients, e.g. vitamins, minerals
• A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Abstract

The present invention relates to a combination of galacto-oligosaccharides (GOS) and a mixture of human milk oligosaccharides (HMOs), or compositions comprising the combination, for use in treating and/or preventing stress and/or a mood disorder in a human over 7 years of age, wherein the mixture of HMOs consists or consists essentially of 2'-fucosyllactose (2'-FL) and difucosyllactose (DFL) or of lacto-N-tetraose (LNT) and 6'-sialyllactose (6'-SL). The present invention also relates to the use of a combination of galacto-oligosaccharides (GOS) and a mixture of human milk oligosaccharides (HMOs), or compositions comprising the combination, for treating and/or preventing stress and/or a mood disorder in a human over 7 years of age, wherein the mixture of HMOs consists or consists essentially of 2'-fucosyllactose (2'-FL) and difucosyllactose (DFL) or of lacto-N-tetraose (LNT) and 6'-sialyllactose (6'-SL).

IPC Classes  ?

• A61K 31/702 - Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
• A61P 25/22 - Anxiolytics
• A61P 25/24 - Antidepressants
• A23L 33/21 - Addition of substantially indigestible substances, e.g. dietary fibres

Abstract

Bifidobacterium animalis ssp. lactisBifidobacterium animalis ssp. lactisFirmicutes, Lachnospiraceae, BlautiaAnaerostipesAnaerostipes bacteria in the intestinal tract.

IPC Classes  ?

• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
• A61P 5/48 - Drugs for disorders of the endocrine system of the pancreatic hormones
• A61P 13/00 - Drugs for disorders of the urinary system
• A61P 17/00 - Drugs for dermatological disorders
• A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 25/26 - Psychostimulants, e.g. nicotine, cocaine
• A61P 31/04 - Antibacterial agents
• A61P 31/18 - Antivirals for RNA viruses for HIV
• A61P 35/00 - Antineoplastic agents
• A61K 35/745 - Bifidobacteria
• A61K 31/375 - Ascorbic acid, i.e. vitamin C; Salts thereof

Abstract

Bacillus coagulansBacillus coagulans in the intestinal tract.

IPC Classes  ?

• A61K 31/525 - Isoalloxazines, e.g. riboflavins, vitamin B2
• A61K 35/742 - Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
• A61P 1/12 - Antidiarrhoeals
• A61P 11/00 - Drugs for disorders of the respiratory system

Abstract

The present invention relates to vitamin B2 (riboflavin) for use in improving gut health in animals and humans. In particular, it was found that vitamin B2, upon delivery to the large intestine, increases the abundance of the beneficial bacteria Lactobacillus rhamnosus in the intestinal tract.

IPC Classes  ?

• A61K 31/525 - Isoalloxazines, e.g. riboflavins, vitamin B2
• A61K 35/747 - Lactobacilli, e.g. L. acidophilus or L. brevis
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
• A61P 1/12 - Antidiarrhoeals
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• A61P 9/00 - Drugs for disorders of the cardiovascular system
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61P 11/12 - Mucolytics
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• A61P 35/00 - Antineoplastic agents
• A61P 37/00 - Drugs for immunological or allergic disorders

Abstract

The present invention relates to vitamins for use in improving gut health in animals and humans. In particular, it was found that, upon delivery to the large intestine, vitamin B2, vitamin C, and vitamin D can be used for increasing the abundance of the beneficial bacteria Bifidobacterium animalis ssp. lactis in the intestinal tract.

IPC Classes  ?

• A61K 35/745 - Bifidobacteria
• A61K 31/525 - Isoalloxazines, e.g. riboflavins, vitamin B2
• A61K 31/375 - Ascorbic acid, i.e. vitamin C; Salts thereof
• A61K 31/593 - 9,10-Secocholestane derivatives, e.g. cholecalciferol, vitamin D3
• A23L 33/15 - Vitamins
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
• A61P 1/14 - Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention relates to a combination comprising vitamin C and Bifidobacterium animalis ssp. lactis and its use for improving gut health in animals and humans. It was found that a combination of vitamin C and Bifidobacterium animalis ssp. lactis, when delivered to the large intestine, increases the abundance of the beneficial Rikenellaceae bacteria in the intestinal tract.

IPC Classes  ?

• A23K 10/18 - Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
• A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics
• A23L 33/15 - Vitamins
• A23K 20/174 - Vitamins

Abstract

Lactobacillus rhamnosusLactobacillus rhamnosusBifidobacteriaceaeBifidobacteriumBifidobacterium bacteria in the intestinal tract.

IPC Classes  ?

• A23K 10/18 - Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
• A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics
• A23L 33/15 - Vitamins
• A23K 20/174 - Vitamins
• A61K 35/747 - Lactobacilli, e.g. L. acidophilus or L. brevis

Abstract

Bifidobacterium animalis ssp. lactisBifidobacterium animalis ssp. lactisParabacteroides distasonisParabacteroides distasonis bacteria in the intestinal tract.

IPC Classes  ?

• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
• A61P 5/48 - Drugs for disorders of the endocrine system of the pancreatic hormones
• A61P 35/00 - Antineoplastic agents
• A61K 35/745 - Bifidobacteria
• A61P 3/02 - Nutrients, e.g. vitamins, minerals
• A61P 3/04 - Anorexiants; Antiobesity agents
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61K 35/74 - Bacteria

Abstract

Bifidobacterium animalis ssp. lactisBifidobacterium animalis ssp. lactisBifidobacterium animalis ssp. lactis, when delivered to the large intestine, increases the concentration of SCFAs, including butyrate, in the intestinal tract.

IPC Classes  ?

• A61P 5/48 - Drugs for disorders of the endocrine system of the pancreatic hormones
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• A61P 37/00 - Drugs for immunological or allergic disorders
• A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
• A61K 31/375 - Ascorbic acid, i.e. vitamin C; Salts thereof
• A61K 35/745 - Bifidobacteria
• A61P 35/00 - Antineoplastic agents
• A61P 3/02 - Nutrients, e.g. vitamins, minerals
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• A61P 3/04 - Anorexiants; Antiobesity agents

Abstract

The present invention relates to a combination comprising vitamin B2 and Lactobacillus rhamnosus and its use for improving gut health in animals and humans. It was found that a combination of vitamin B2 and Lactobacillus rhamnosus, when delivered to the large intestine, increases the abundance of beneficial Verrucomicrobia, Akkermansiaceae and Akkermansia bacteria in the intestinal tract.

IPC Classes  ?

• A61K 35/747 - Lactobacilli, e.g. L. acidophilus or L. brevis
• A61K 31/525 - Isoalloxazines, e.g. riboflavins, vitamin B2
• A23L 33/15 - Vitamins
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• A61P 3/00 - Drugs for disorders of the metabolism
• A61P 3/04 - Anorexiants; Antiobesity agents
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• A61P 13/08 - Drugs for disorders of the urinary system of the prostate
• A61P 35/00 - Antineoplastic agents
• A61P 25/00 - Drugs for disorders of the nervous system

Abstract

Bacillus coagulansBacillus coagulansTannerellaceaeParabacteroides distasonisParabacteroides distasonis bacteria in the intestinal tract.

IPC Classes  ?

• A61K 31/375 - Ascorbic acid, i.e. vitamin C; Salts thereof
• A61K 35/742 - Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
• A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• A61P 3/04 - Anorexiants; Antiobesity agents
• A61P 5/48 - Drugs for disorders of the endocrine system of the pancreatic hormones
• A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
• A61P 35/00 - Antineoplastic agents
• A61P 37/00 - Drugs for immunological or allergic disorders

Abstract

Lactobacillus rhamnosus Lactobacillus rhamnosusChristensenellaceaeChristensenellaceae bacteria in the intestinal tract.

IPC Classes  ?

• A61P 1/18 - Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
• A61P 3/04 - Anorexiants; Antiobesity agents
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• A61P 9/00 - Drugs for disorders of the cardiovascular system
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
• A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
• A61P 25/24 - Antidepressants
• A61K 31/375 - Ascorbic acid, i.e. vitamin C; Salts thereof
• A61K 35/747 - Lactobacilli, e.g. L. acidophilus or L. brevis
• A61P 3/02 - Nutrients, e.g. vitamins, minerals

Abstract

Bacillus coagulansBacillus coagulansFirmicutes, LachnospiraceaeAnaerostipes hadrusAnaerostipes hadrus bacteria in the intestinal tract.

IPC Classes  ?

• A61K 35/742 - Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
• A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• A61P 37/00 - Drugs for immunological or allergic disorders
• A61K 31/375 - Ascorbic acid, i.e. vitamin C; Salts thereof
• A61K 31/525 - Isoalloxazines, e.g. riboflavins, vitamin B2
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys

Abstract

The present invention relates to a combination comprising vitamin C and Lactobacillus rhamnosus and its use for improving gut health in animals and humans. It was found that a combination of vitamin C and Lactobacillus rhamnosus, when delivered to the large intestine, increases the concentration of butyrate in the intestinal tract.

IPC Classes  ?

• A61K 35/747 - Lactobacilli, e.g. L. acidophilus or L. brevis
• A61P 3/04 - Anorexiants; Antiobesity agents
• A61P 5/48 - Drugs for disorders of the endocrine system of the pancreatic hormones
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• A61P 35/00 - Antineoplastic agents
• A61P 37/00 - Drugs for immunological or allergic disorders
• A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
• A61K 31/375 - Ascorbic acid, i.e. vitamin C; Salts thereof
• A61P 3/02 - Nutrients, e.g. vitamins, minerals

Abstract

The present invention relates to a combination comprising vitamin B2 and Lactobacillus rhamnosus and its use for improving gut health in animals and humans. It was found that a combination of vitamin B2 and Lactobacillus rhamnosus, when delivered to the large intestine, increases the abundance of beneficial Firmicutes and Lachnospiraceae bacteria in the intestinal tract.

IPC Classes  ?

• A61K 31/525 - Isoalloxazines, e.g. riboflavins, vitamin B2
• A61K 35/747 - Lactobacilli, e.g. L. acidophilus or L. brevis
• A61P 3/02 - Nutrients, e.g. vitamins, minerals

Abstract

The present invention relates to a fish feed or fish feed additive comprising one or more polypeptides having a phytase activity, wherein said phytase activity comprising EC: 3.1.3.26 (i.e., 4-phytase) and/or EC 3.1.3.8 (i.e., 3-phytase) and/or EC 3.1.3.72 (i.e., 5-phytase) phytase activity, wherein said phytase activity is dosed at a level which is at least 10% less than a efficient (e.g., optimal) dose of phytase activity configured for maximum fish growth response. The present invention relates to a method for reducing phosphorus secretion and/or excretion by a fish, said method comprising: administering the animal feed or animal feed additive according to any one of preceding claims.

IPC Classes  ?

• A23K 10/14 - Pretreatment of feeding-stuffs with enzymes
• A23K 20/189 - Enzymes
• A23K 20/26 - Compounds containing phosphorus
• A23K 50/80 - Feeding-stuffs specially adapted for particular animals for aquatic animals, e.g. fish, crustaceans or molluscs

Abstract

The present invention relates to a method of improving pigmentation in an aquatic animal comprising administering to the animal an animal feed or animal feed additive comprising vitamin D or a vitamin D metabolite, preferably 25-hydroxy vitamin D3 (25-OH D3).

IPC Classes  ?

• A23K 50/80 - Feeding-stuffs specially adapted for particular animals for aquatic animals, e.g. fish, crustaceans or molluscs
• A23K 20/174 - Vitamins
• A23K 20/179 - Colouring agents, e.g. pigmenting or dyeing agents

Abstract

Joint spacers are disclosed. In an embodiment, the joint spacers are biostable and have a first side (3) comprising a convex portion (5) and a peripheral portion (6) surrounding the convex portion. The convex portion comprises a foam (1) and the foam has a porosity in the peripheral portion that is less than the porosity at the thickest point of the convex portion.

IPC Classes  ?

• A61B 17/56 - Surgical instruments or methods for treatment of bones or joints; Devices specially adapted therefor
• A61F 2/08 - Muscles; Tendons; Ligaments
• A61F 2/30 - Joints
• A61F 2/38 - Joints for elbows or knees

Abstract

Joint spacers are disclosed. In an embodiment, a joint spacer comprises a foam (1), a first articular surface (3) and a second articular surface (4). The foam has a first porosity at a first location and a second porosity, less than the first porosity, at a second location. In an embodiment, the first porosity is more proximate a first external surface (5) of the joint spacer and the second location is more proximate a second external surface (6) of the joint spacer.

IPC Classes  ?

• A61F 2/30 - Joints
• A61F 2/38 - Joints for elbows or knees
• A61B 17/56 - Surgical instruments or methods for treatment of bones or joints; Devices specially adapted therefor
• A61F 2/08 - Muscles; Tendons; Ligaments

Abstract

The invention relates to the field of bakery ingredients. More specifically, the invention relates to a variant of a parent polypeptide, wherein the difference between the variant polypeptide and the parent polypeptide is that a KEX2 protease cleavage site which is present in the parent polypeptide, is absent in the variant polypeptide. The invention further relates to a process for preparing a dough wherein a variant polypeptide as disclosed herein is used and baked product prepared from the dough.

IPC Classes  ?

• A21D 8/04 - Methods for preparing dough; Treating dough prior to baking treating dough with microorganisms or enzymes
• C12N 9/20 - Triglyceride splitting, e.g. by means of lipase

Abstract

The present invention relates to the use of the use of a blend of sugars comprising psicose, mannose, fructose and glucose to increase the expression of cytokeratin-1 in skin to strengthen skin's self-defense mechanisms and maintain skin integrity.

IPC Classes  ?

• A61K 8/60 - Sugars; Derivatives thereof
• A61Q 19/00 - Preparations for care of the skin
• A61P 17/00 - Drugs for dermatological disorders

Abstract

The present invention is related to fermentative production of isoprenoids, lipids, and sterols, particularly various forms of vitamin E and vitamin D3, as well as various polyunsaturated fatty acids (PUFAs), including derivatives or intermediates, comprising cultivation of a suitable host cell, such as fungal host cell, particularly oleaginous host cell, in an improved two-phase culture system. The two-phase culture system comprises in situ extraction of said isoprenoids, lipids or sterols, or a partial in situ extraction of said lipids, wherein a suitable host cell is cultivated in the presence of a carbon source and a lipophilic solvent, wherein the lipophilic solvent is different from the carbon source and with a minimal loss of solvent during the fermentation process. Preferably, the lipophilic solvent is selected from isoparaffins, such as e.g. from Isopar L or Isopar M.

IPC Classes  ?

• C12P 5/00 - Preparation of hydrocarbons
• B01D 11/00 - Solvent extraction
• C12P 7/64 - Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
• C12P 7/6463 - Glycerides obtained from glyceride producing microorganisms, e.g. single cell oil
• C12P 33/00 - Preparation of steroids

Abstract

A mutant yeast cell, comprising : (i) a first genetic modification for expression of a NAD+ dependent protein that functions in a first metabolic pathway converting a sugar alcohol into a fermentation product; and (ii) a second genetic modification for expression of a protein that functions in a second metabolic pathway forming a non-native redox sink. And process using such a yeast cell.

IPC Classes  ?

• C12N 1/16 - Yeasts; Culture media therefor
• C12N 15/63 - Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
• C12N 15/81 - Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
• C12P 7/06 - Ethanol, i.e. non-beverage

Abstract

The present inventions relate to processes for producing cannabis distillates using enzymes to treat cannabis oleoresin.

IPC Classes  ?

• B01D 11/02 - Solvent extraction of solids

Abstract

The present disclosure relates to improved strains for the production of Human Milk Oligosaccharides (HMOs) in large scale. The strains are genetically engineered to produce less acetate and/or ethanol during large-scale fermentation, in particular when encountering gradients with excess carbon source in the fermenter.

IPC Classes  ?

• C12P 19/18 - Preparation of compounds containing saccharide radicals produced by the action of a glycosyl transferase, e.g. alpha-, beta- or gamma-cyclodextrins
• C12N 9/10 - Transferases (2.)
• C12N 9/88 - Lyases (4.)

Abstract

The present invention relates to a texturized vegetable protein having a length within the range of 3 to 8 cm, preferably within the range of 3.5 to 6 cm, having a width within the range of 1 to 3 cm, wherein the protein comprises a legume protein. As well as to a process for manufacturing a texturized vegetable protein particle. The present invention also relates to meat analogue products comprising the texturized vegetable protein particle.

IPC Classes  ?

• A23J 1/14 - Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites from press-cake or oil-bearing seeds
• A23J 3/14 - Vegetable proteins
• A23J 3/22 - Working-up of proteins for foodstuffs by texturising
• A23J 3/26 - Working-up of proteins for foodstuffs by texturising using extrusion or expansion
• A23P 30/20 - Extruding

Abstract

The present invention relates to new specific Urolithin butyrate compounds and to the synthesis of these specific Urolithin butyrates as well as to new compounds and their use. Butyrate compounds are very useful compounds, either as such or as intermediates in organic synthesis.

IPC Classes  ?

• C07D 311/80 - Dibenzopyrans; Hydrogenated dibenzopyrans

Abstract

The present invention relates to a yeast extract comprising free glutamate in an amount of at least 7 wt. % on salt free dry matter and comprising an amount of 5'-ribonucleotides of at least 10 wt. % on salt free dry matter.

IPC Classes  ?

• A23L 27/00 - Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
• A23L 31/15 - Extracts

Abstract

The present invention relates to the use of a blend of sugars comprising psicose, mannose, fructose and glucose to suppress the discoloration of vitamin B12 in aqueous compositions. Furthermore, the invention relates to aqueous compositions comprising said blend, Vitamin B12 and one or more preservatives selected from phenoxyethanol, (ethyl)hexylglycerin and/ or an 10 1,2-alkandiol.

IPC Classes  ?

• A61K 8/67 - Vitamins
• A61K 8/60 - Sugars; Derivatives thereof
• A61K 8/34 - Alcohols
• A61Q 90/00 - Cosmetics or similar toiletry preparations for specific uses not provided for in other groups of this subclass

Abstract

The present invention relates to the use of psicose to suppress the discoloration of vitamin B12 in aqueous compositions. Furthermore, the invention relates to aqueous compositions comprising psicose, Vitamin B12 and optionally one or more preservatives selected from phenoxyethanol, (ethyl)hexylglycerin and/ or an 1,2-alkandiol.

IPC Classes  ?

• A61K 8/67 - Vitamins
• A61K 8/60 - Sugars; Derivatives thereof
• A61K 8/34 - Alcohols
• A61Q 90/00 - Cosmetics or similar toiletry preparations for specific uses not provided for in other groups of this subclass

Abstract

The present invention relates to the increase of water resistance of cosmetic compositions which comprise pigments. This is achieved by the combined use of a mixture of branched and linear saturated C15-C19 alkanes; and an ester of a fatty acid and dextrin.

IPC Classes  ?

• A61K 8/31 - Hydrocarbons
• A61K 8/73 - Polysaccharides
• A61Q 1/00 - Make-up preparations; Body powders; Preparations for removing make-up

Abstract

The present invention relates to cosmetic composition comprising UV- filter(s), an ester of a fatty acid and dextrin and a mixture of branched and linear saturated C15-C19, wherein said mixture comprised primarily branched saturated C15-C19 and a specific cellulose derivative. This cosmetic composition shows a significantly increased water resistance.

IPC Classes  ?

• A61K 8/31 - Hydrocarbons
• A61K 8/73 - Polysaccharides
• A61Q 1/00 - Make-up preparations; Body powders; Preparations for removing make-up
• A61Q 17/04 - Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations

Abstract

It is disclosed a new crystalline form of lacto-N-triose II, a method to obtain the same and nutritional or pharmaceutical compositions comprising the same.

IPC Classes  ?

• C07H 1/06 - Separation; Purification
• C07H 5/06 - Aminosugars
• A23L 29/30 - Foods or foodstuffs containing additives; Preparation or treatment thereof containing starch hydrolysates, e.g. dextrin

Abstract

The present invention relates to a method for improving performance of a layer bird by administering a nutritional composition comprising an oligosaccharide preparation to the layer bird, and to a use of an oligosaccharide preparation to improve performance of a layer bird.

IPC Classes  ?

• A23K 20/163 - Sugars; Polysaccharides
• A23K 50/75 - Feeding-stuffs specially adapted for particular animals for birds for poultry

Abstract

The present disclosure relates to the production of sialylated Human Milk Oligosaccharides (HMOs), in particular to the production of sialyl-lacto-N-tetraose a (LST-a), from precursor oligosaccharides and the genetic engineering of suitable cells for use in said production, as well as to methods for producing said sialylated HMOs.

IPC Classes  ?

• C12N 15/70 - Vectors or expression systems specially adapted for E. coli
• A61K 31/702 - Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
• C12N 9/10 - Transferases (2.)

Abstract

The present disclosure relates to the production of mixtures of sialylated Human Milk Oligosaccharides (HMOs), in particular 3'SL and 6'SL and genetically modified cells and their use in said production, where the cells express a heterologous sialyltransferase with dual α-2,3-sialyltransferase/α-2,6-sialyltransferase activity.

IPC Classes  ?

• C12N 15/70 - Vectors or expression systems specially adapted for E. coli
• A61K 31/702 - Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
• C12N 9/10 - Transferases (2.)

Abstract

The present invention relates to the use of certain 4-amidino benzylamines as ingredient to increase skin firmness and elasticity by increasing type I collagen expression in the skin.

IPC Classes  ?

• A61K 8/46 - Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
• A61Q 19/08 - Anti-ageing preparations

Abstract

The present invention relates to a new formulation, which comprises a high amount of retinol, which has a defined mixture of cis and trans isomers, in a specific solvent and in the presence of mixed tocopherol.

IPC Classes  ?

• A61K 8/31 - Hydrocarbons
• A23L 33/15 - Vitamins
• A23L 33/155 - Vitamins A or D
• A61K 8/67 - Vitamins
• A61Q 19/08 - Anti-ageing preparations
• A61K 8/34 - Alcohols
• A61K 8/92 - Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products

Abstract

The present invention relates to a new formulation comprising a mixture of lutein and zeaxanthin in a specific ratio, polysorbate and water. The formulation can be used in a variety of products (such food, feed, dietary supplements, pharmaceuticals, or other products).

IPC Classes  ?

• A23L 5/44 - Addition of dyes or pigments, e.g. in combination with optical brighteners using naturally occurring organic dyes or pigments, their artificial duplicates or their derivatives using carotenoids or xanthophylls
• A23L 29/10 - Foods or foodstuffs containing additives; Preparation or treatment thereof containing emulsifiers

Abstract

The present invention relates to a new formulation, which comprises a high amount of retinol, which has a defined mixture of cis and trans isomers, in a specific solvent and in the presence of mixed tocopherol.

IPC Classes  ?

• A61K 8/31 - Hydrocarbons
• A23L 33/15 - Vitamins
• A23L 33/155 - Vitamins A or D
• A61K 8/67 - Vitamins
• A61Q 19/08 - Anti-ageing preparations
• A61K 8/37 - Esters of carboxylic acids

Abstract

The present invention relates to a new formulation, which comprises a high amount of retinol, which has a defined mixture of cis and trans isomers, in a specific solvent and in the presence of mixed tocopherol.

IPC Classes  ?

• A61K 8/31 - Hydrocarbons
• A23L 33/15 - Vitamins
• A23L 33/155 - Vitamins A or D
• A61K 8/67 - Vitamins
• A61Q 19/08 - Anti-ageing preparations

Abstract

The present invention provides an electrochemical process for producing a benzoquinone compound, which is versatile in converting hydroquinone and a broad range of phenols into benzoquinones in an attractive yield and selectivity without the need to modify the protocol. The process of the present invention avoids cost-intensive catalysts, reagents and oxidants and does not provide reagent waste, so it is cost effective and environment friendly.

IPC Classes  ?

• C25B 3/07 - Oxygen containing compounds
• C25B 3/09 - Nitrogen containing compounds
• C25B 3/11 - Halogen containing compounds
• C25B 3/23 - Oxidation
• C25B 9/15 - Flow-through cells
• C25B 11/043 - Carbon, e.g. diamond or graphene
• C25B 11/052 - Electrodes comprising one or more electrocatalytic coatings on a substrate
• C25B 11/091 - Electrodes formed of electrocatalysts on a substrate or carrier characterised by the electrocatalysts material consisting of two or more catalytic elements or catalytic compounds
• C25B 11/093 - Electrodes formed of electrocatalysts on a substrate or carrier characterised by the electrocatalysts material consisting of two or more catalytic elements or catalytic compounds at least one noble metal or noble metal oxide and at least one non-noble metal oxide
• C07C 46/06 - Preparation of quinones by oxidation giving rise to quinoid structures of at least one hydroxy group on a six-membered aromatic ring

Abstract

The present invention relates to a method for modulating the level of one or more secondary metabolite(s), and a use for modulating the level of one or more secondary metabolite(s) in the gastrointestinal tract of an animal.

IPC Classes  ?

• A23K 20/163 - Sugars; Polysaccharides
• A23K 10/16 - Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
• A23K 10/18 - Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
• A23K 20/189 - Enzymes
• A23K 50/10 - Feeding-stuffs specially adapted for particular animals for ruminants
• A23K 50/30 - Feeding-stuffs specially adapted for particular animals for swine
• A23K 50/75 - Feeding-stuffs specially adapted for particular animals for birds for poultry
• A23L 33/125 - Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing starch hydrolysates
• A61K 31/70 - Carbohydrates; Sugars; Derivatives thereof
• A61K 31/702 - Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
• A61P 25/00 - Drugs for disorders of the nervous system

Abstract

Polyesteramide (PEA) copolymers are disclosed, having structures that include repeating units that contain various monomer residues characterized herein and present in the repeating units at defined ranges of molar equivalents. These copolymers can possess a number of important advantages for providing longer performing glucose sensors and/or for simplifying their design. For example, in vivo modeling has confirmed that these polymers exhibit both decreased collagen deposition and increased neovascularization (angiogenesis). Additional testing has demonstrated favorable oxygen and glucose transport capabilities, as well as other relevant properties.

IPC Classes  ?

• C08G 69/10 - Alpha-amino-carboxylic acids
• C08G 69/36 - Polyamides derived from amino carboxylic acids or from polyamines and polycarboxylic acids derived from amino acids, polyamines, and polycarboxylic acids
• C08G 69/44 - Polyester-amides
• C09D 177/04 - Polyamides derived from alpha-amino carboxylic acids
• C09D 177/12 - Polyester-amides
• A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration, pH-value

Abstract

The invention relates to a dry extrusion process for preparing a texturized vegetable protein comprising extruding a mixture of rapeseed protein, a legume derived protein and calcium carbonate, to a composition comprising rapeseed protein, a legume-derived protein, calcium and a plant-based fiber, to the use of said composition in the preparation of a meat alternative and to meat alternatives. It also relates to the use of calcium carbonate for improving the hydration rate, water holding capacity and/or density of a texturized vegetable protein comprising rapeseed protein.

IPC Classes  ?

• A23J 3/14 - Vegetable proteins
• A23J 3/16 - Vegetable proteins from soybean
• A23J 3/22 - Working-up of proteins for foodstuffs by texturising
• A23J 3/26 - Working-up of proteins for foodstuffs by texturising using extrusion or expansion

Abstract

SaccharomycetalesSaccharomycetales yeast cells, as well as to the use of said animal feed for feeding an animal and/or for increasing body weight of an animal.

IPC Classes  ?

• A23K 10/16 - Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
• A23K 10/22 - Animal feeding-stuffs from material of animal origin from fish
• A23K 10/30 - Animal feeding-stuffs from material of fungal origin, e.g. mushrooms
• A23K 50/80 - Feeding-stuffs specially adapted for particular animals for aquatic animals, e.g. fish, crustaceans or molluscs

Abstract

Disclosed herein are membranes, composition for forming membranes, methods for forming membranes, and sensors and devices comprising membranes. The membrane comprises the reaction product of a diisocyanate, a polymeric aliphatic diol, a first chain extender diol, and a second chain extender diol, wherein the first chain extender diol and second chain extender diol are different and satisfy at least one of aspecified set of relationships.

IPC Classes  ?

• C08G 18/32 - Polyhydroxy compounds; Polyamines; Hydroxy amines
• C08G 18/48 - Polyethers
• C08G 18/61 - Polysiloxanes
• C08G 18/65 - Low-molecular-weight compounds having active hydrogen with high-molecular-weight compounds having active hydrogen
• C08G 18/66 - Compounds of groups , , or
• C08G 18/76 - Polyisocyanates or polyisothiocyanates cyclic aromatic
• C08G 18/40 - High-molecular-weight compounds
• A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration, pH-value
• B01D 71/54 - Polyureas; Polyurethanes

Abstract

Streptococcus suisStreptococcus suis.

IPC Classes  ?

• A23K 50/30 - Feeding-stuffs specially adapted for particular animals for swine
• A23K 20/10 - Organic substances
• A23K 20/111 - Aromatic compounds
• A61K 31/05 - Phenols
• A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid

Abstract

Disclosed are drug delivery devices, coatings, and microparticles that achieve sufficiently small particle sizes with high loading of Rapamycin. In an embodiment, a balloon comprises a coating on its exterior surface, the coating comprising microparticles having a Dv90 particle size of from 1 to 11 µm, as measured with static laser scattering, the microparticles comprising from 35 to 50 wt% of rapamycin, based on the total weight of the microparticles, and a random copolymer according to Formula (I).

IPC Classes  ?

• A61L 29/08 - Materials for coatings
• A61L 29/14 - Materials characterised by their function or physical properties
• A61L 29/16 - Biologically active materials, e.g. therapeutic substances
• A61L 31/10 - Macromolecular materials
• A61L 31/14 - Materials characterised by their function or physical properties
• A61L 31/16 - Biologically active materials, e.g. therapeutic substances
• A61K 9/70 - Web, sheet or filament bases
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/5575 - Eicosanoids, e.g. leukotrienes having a cyclopentane ring, e.g. prostaglandin E2, prostaglandin F2-alpha
• A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
• A61K 9/50 - Microcapsules

Abstract

The present invention relates to an aquaculture feed composition comprising an optimum concentration of at least three fatty acids selected from LOA, LNA, ARA, EPA and DHA to improve stress resistance. The invention further concerns a method of producing an aquaculture meat product, by feeding farmed fish an aquaculture feed composition, said method comprising the step of formulating aquaculture feed composition comprising an optimum concentration of at least three fatty acids selected from LOA, LNA, ARA, EPA and DHA to improve stress resistance of the farmed fish. The optimum concentration of said at least three fatty acids is adapted to the breed of the fish, and the different stages of growth of the fish as determined by its weight.

IPC Classes  ?

• A23K 20/158 - Fatty acids; Fats; Products containing oils or fats
• A23K 50/80 - Feeding-stuffs specially adapted for particular animals for aquatic animals, e.g. fish, crustaceans or molluscs

Abstract

The present invention is related to a novel process on biological production of lipophilic substances in an oleaginous host cell, particularly Yarrowia lipolytica, comprising modification in the N-glycosylation pathway, leading to higher yield and product purity with further facilitating the overall production process.

IPC Classes  ?

• C12N 9/10 - Transferases (2.)
• C07C 403/24 - Derivatives of cyclohexane or of a cyclohexene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene rings, e.g. vitamin A, beta-carotene, beta-i having side-chains substituted by six-membered non-aromatic rings, e.g. beta-carotene
• C07K 14/39 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts
• C12N 15/81 - Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
• C12P 7/6463 - Glycerides obtained from glyceride producing microorganisms, e.g. single cell oil
• C12P 7/6472 - Glycerides containing polyunsaturated fatty acid [PUFA] residues, i.e. having two or more double bonds in their backbone

Abstract

The present disclosure provides a method for increasing production of a polyunsaturated fatty acid, especially eicosapentaenoic acid (EPA), in a microorganism, comprising adjusting the macro- and/or micronutrients during fermentation. The invention includes any culture, biomass, and oil produced by the method.

IPC Classes  ?

• C12P 7/64 - Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
• C12N 1/12 - Unicellular algae; Culture media therefor
• C12P 7/6432 - Eicosapentaenoic acids [EPA]
• C12P 7/6434 - Docosahexenoic acids [DHA]
• C12R 1/89 - Algae

Abstract

Disclosed herein are compositions and methods for forming nutritional compositions comprising genistein. In an embodiment, an orally consumable nutritional supplement comprises a thickening agent, genistein, and a saffron extract, wherein the weight ratio of genistein to the saffron extract is from about 2:1 to about 1:2. The disclosed compositions may exhibit improved settling behavior of genistein and/or may be useful for treating the physical and emotional symptoms of perimenopause and menopause.

IPC Classes  ?

• A61K 36/48 - Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
• A61K 36/487 - Psoralea
• A61K 36/488 - Pueraria (kudzu)
• A61P 5/30 - Oestrogens
• A61K 31/11 - Aldehydes
• A61K 31/202 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having three or more double bonds, e.g. linolenic acid
• A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
• A61K 31/7028 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
• A61K 31/732 - Pectin
• A61K 36/88 - Liliopsida (monocotyledons)
• A61K 47/36 - Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
• A23L 29/231 - Pectin; Derivatives thereof
• A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives
• A61K 9/68 - Medicinal preparations characterised by special physical form chewing gum type
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 47/12 - Carboxylic acids; Salts or anhydrides thereof
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Abstract

A process for producing thiolactone compounds, or geometrical isomers thereof or geometrical isomeric mixtures thereof is provided. The process avoids expensive reagents, improves yield and thus is more efficient and suitable in industry.

IPC Classes  ?

• C07B 37/10 - Cyclisation
• C07D 513/00 - Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups , or

Abstract

The present invention relates to the use of neutral core human milk oligosaccharides such as in particular lacto-N-(neo)tetraoses as anti-ageing active ingredient as well as the use thereof in topical anti-ageing compositions.

IPC Classes  ?

• A61K 8/60 - Sugars; Derivatives thereof
• A61K 8/98 - Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof, of undetermined constitution of animal origin
• A61L 15/28 - Polysaccharides or their derivatives
• A61Q 19/08 - Anti-ageing preparations
• A61K 31/70 - Carbohydrates; Sugars; Derivatives thereof

Abstract

The present invention relates to a composition for aquatic animals comprising as active ingredient 25-hydroxyvitamin D, preferably 25-hydroxy vitamin D3 (25-OH D3). The present invention further relates to the use of 25-hydroxyvitamin D, preferably 25-hydroxyvitamin D3 (25-OH D3), as feed additive for aquatic animals including fish and shrimp. More particular, this invention relates to the use of 25-hydroxyvitamin D, preferably 25-hydroxyvitamin D3 (25-OH D3), for improving feed utilization and growth and performance parameters of the animals, such as the feed conversion ratio (FOR), Immunity, protein efficiency ratio (PER), specific growth rate (SGR), final body weight, feed efficiency (FE), nutrient utilization, body protein content, and/or carcass yield and/or for increasing levels of Vitamin D, preferably Vitamin D3, in the blood of aquatic animals.

IPC Classes  ?

• A23K 20/174 - Vitamins
• A23K 40/25 - Shaping or working-up of animal feeding-stuffs by extrusion
• A23K 50/80 - Feeding-stuffs specially adapted for particular animals for aquatic animals, e.g. fish, crustaceans or molluscs
• A23K 20/158 - Fatty acids; Fats; Products containing oils or fats
• A23K 40/30 - Shaping or working-up of animal feeding-stuffs by coating

Abstract

The present invention provides a method for improving performance, immunity and/or gut health of animals comprising administering to the animals one or more microbial muramidase(s) and one or more organic acid(s).

IPC Classes  ?

• A23K 20/111 - Aromatic compounds
• A23K 20/158 - Fatty acids; Fats; Products containing oils or fats
• A23K 20/189 - Enzymes
• A23K 50/30 - Feeding-stuffs specially adapted for particular animals for swine
• A23K 50/60 - Feeding-stuffs specially adapted for particular animals for weanlings